Andrew R. Adams
Mairs & Power Growth Fund
Mairs & Power Growth Fund Abbott Laboratories stake
total: 96
Mairs & Power Growth Fund ABT trades
- Total transactions:
- 11
- New positions:
- 1
- Sold out:
- 1
- Reduced:
- 9
- Held since:
- 2019 Q3
- Held for:
- 24 quarters
- Latest activity:
- 2025 Q3
According to 2026 Q2 report, Mairs & Power Growth Fund doesn't hold any Abbott Laboratories (ABT) shares. To date, the estimated cost basis is nearly $83.67 for "buy" trades and estimated average "sell" price is $101.75. Mairs & Power Growth Fund first purchased ABT in 2019 Q3, initially acquiring about 1.15M shares. Since the initial investment in Abbott Laboratories (ABT), Mairs & Power Growth Fund has made 10 more transactions.
When did Mairs & Power Growth Fund sell Abbott Laboratories (ABT)?
Mairs & Power Growth Fund sold off the entire Abbott Laboratories (ABT) position in 2025 Q3.
When did Mairs & Power Growth Fund buy Abbott Laboratories (ABT)?
Mairs & Power Growth Fund first invested in Abbott Laboratories (ABT) in 2019 Q3 at the reported quarter-end price of $83.67 per share.
What's the cost basis of Mairs & Power Growth Fund's ABT stake?
The estimated cost basis for Abbott Laboratories (ABT) stake is around $83.67 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $83.67
- Weighted AVG sell price:
- $101.75
Mairs & Power Growth Fund's historical trades in Abbott Laboratories
11 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2025 Q3
|
0.00%
|
0
|
$136.01
|
|
-100% (-118,361)
|
-0.3%
|
|
2025 Q2
|
0.30%
|
118,361
|
$136.01
|
$16,098,280
|
-48.16% (-109,977)
|
-0.29%
|
|
2025 Q1
|
0.59%
|
228,338
|
$132.65
|
$30,289,036
|
-10.75% (-27,491)
|
-0.07%
|
|
2024 Q2
|
0.48%
|
255,829
|
$103.91
|
$26,583,191
|
-37.80% (-155,475)
|
-0.3%
|
|
2023 Q1
|
0.91%
|
411,304
|
$101.26
|
$41,648,643
|
-6.57% (-28,908)
|
-0.07%
|
|
2022 Q4
|
1.12%
|
440,212
|
$109.79
|
$48,330,875
|
-14.52% (-74,788)
|
-0.19%
|
|
2020 Q3
|
1.28%
|
$108.83
|
-8.04% (-45,000)
|
|||
|
2020 Q2
|
1.23%
|
$91.43
|
-13.26% (-85,600)
|
|||
|
2020 Q1
|
1.40%
|
$78.91
|
-23.65% (-200,000)
|
|||
|
2019 Q4
|
1.59%
|
$86.86
|
-26.19% (-300,000)
|
|||
|
2019 Q3
|
2.19%
|
$83.67
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.